Verapamil reverts acute renal functional impairment induced by angiotensin II converting enzyme inhibitors

Renal Failure

Volumn 25, Issue 5, 2003, Pages 727-737

  Macías Núñez, Juan F ^a   Fernández, Raul ^b   Calvo, Carlos ^c   Grande, Jesus ^d   Herrera, Julio ^e   Bustamante, Jesus ^f   Garay, Ricardo ^g   Robles, Ricardo ^h   López Novoa, José M ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Laboratorios Knoll SA   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

^d HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^e HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^g INSERM   (France)

^h HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

ACE Inhibitors; Hypertension; Renal failure; Serum creatinine; Verapamil

Indexed keywords

CAPTOPRIL; CILAZAPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; VERAPAMIL;

ACUTE KIDNEY FAILURE; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CREATININE; DRUG ANTAGONISM; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; INDOLES; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VERAPAMIL;

EID: 18244419524     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-120024288     Document Type: Article

References (40)

1. Hollenberg, N.K.; Raij, L. Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy. Arch. Intern. Med. 1993, 153, 2426-2435.
2. ter Wee, P.M.; DeMicheli, A.G.; Epstein, M. Effects of calcium antagonists on renal hemodynamics and progression of nondiabetic chronic renal disease. Arch. Intern. Med. 1994, 154, 1185-1202.
3. Lewis, E.J.; Hunsicker, L.G.; Bain, R.P.; Rohde, R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the collaborative study Group. N. Engl. J. Med. 1993, 329, 1456-1462.
4. Ravid, M.; Lang, R.; Rachmani, R.; Lishner, M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in noninsulin-dependent mellitus. A 7-year follow-up study. Arch. Intern. Med. 1996, 156, 286-289.
5. Ruggenenti, P.; Perna, A.; Gherardi, G.; Garini, G.; Zocalli, C.; Salvadori, M.; Scolari, F.; Schena, F.P.; Remuzzi, G. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with nonnephrotic proteinuria. The Lancet 1999, 354, 359-364.
6. Toto, R.; Mitchell, H.; Lee, H.; Milan, C.; Pettinger, W. Reversible renal insufficiency due to angiotensin converting enzyme inhibitors in hypertensive nephrosclerosis. Ann. Intern. Med. 1991, 115, 513-519.
7. Gotloib, L.; Jaichenko, S.; Fudin, R.; Shostok, A. Severe reduction of renal function in hypertensive and/or diabetics induced by angiotensin-converting enzyme inhibitors. Nephron 1995, 71, 230-231.
8. Toto, R.D. Renal insufficiency due to angiotensin-converting enzyme inhibitors. Miner Electrolyte Metab. 1994, 20, 193-200.
9. Bakris, G.L.; Weir, M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch. Intern. Med. 2000, 160, 685-693.
10. Bakris, G.L.; Willians, B. Angiotensin converting enzyme inhibitors and calcium antagonist alone or combined: does the progression of diabetic renal disease differ? J. Hipertens. 1995, 13 (suppl 2), S95-S101.
11. Griffin, K.A.; Picken, M.M.; Bakris, G.; Bidani, A. Class differences in the effects of calcium blockers in the rat remnant kidney model. Kidney Int. 1999, 55, 1849-1860.
12. Abbott, K.C.; Bakris, G. Renal effects of antihypertensive medications: an overview. J. Clin. Pharmacol. 1993, 33, 392-399.
13. Shultz, P.J.; Raij, L. Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension 1990, 15 (suppl I), 176-180.
14. Epstein, M. Calcium antagonists and renal protection. Arch. Intern. Med. 1992, 152, 1573-1584.
15. Hoelscher, D.; Bakris, G. Antihypertensive therapy and progression of diabetic renal disease. J. Cardiovas. Pharmacol. 1994, 23 (suppl 1), S34-S38.
16. Münter, K.; Hergenroder, S.; Jochims, K.; Kirchengast, M. Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopatic changes in the stroke prone rats. J. Am. Soc. Nephrol. 1996, 7, 681-686.
17. Flores, O.; Arévalo, M.; Gallego, B.; Hidalgo, F.; Vidal, S.; López-Novoa, J.M. Beneficial effect of the long-term treatment with the combination of an ACE Inhibitor and a calcium channel blocker on renal injury in rats with 5/6 nephrectomy. Exp. Nephrol. 1998, 6, 39-49.
18. Bitar, R.; Martín, B.; López-Novoa, J.M.; Macías-Núñez, J.F. Reduction of renal function by angiotensin-converting enzyme inhibitors. Effect of verapamil. Nephron 1997, 75, 486-487.
19. Bosnes, R.W.; Tausski, H.A. The colorimetric determination of creatinine of the Jaffé reaction. J. Biol. Chem. 1945, 158, 581-583.
20. Garg, R.; Yusuf, S. for the collaborative group on ACE inhibitor trials: overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995, 273, 1450-1456.
21. Echemann, M.; Zannad, F.; Briancon, S.; Juillière, Y.; Mertés, P.M.; Virion, J.M.; Villemot, J.P. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular dysfunction: the EPICAL study. Am. Heart J. 2000, 139, 624-631.
22. Zanchi, A.; Brunner, H.; Waeber, B.; Bumier, M. Renal hemodynamic and protective effects of calcium antagonists in hypertension. J. Hypertens. 1995, 13, 1363-1375.
23. Meyer, T.W.; Anderson, S.; Rennke, H.G.; Brenner, B.M. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int. 1987, 31, 752-729.
24. Fenoy, F.J.; Scicli, G.; Carretero, O.; Roman, R.J. Effect of angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 1991, 17, 1038-1044.
25. Regoli, D.; Barabe, J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 1980, 32, 1-46.
26. Bascands, J.L.; Pecher, C.; Rouaud, S.; Emond, C.; Tack, J.L.; Bastie, M.J.; Burch, R.; Regoli, D.; Girolami, J.P. Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. Am. J. Physiol. 1993, 264, F548-F556.
27. Edmond, C.; Bascands, J.L.; Cabos-Boutot, G.; Pecher, C.; Girolami, J.P. Effects of change in sodium and water intake on on glomerular B2-kinin site. Am. J. Physiol. 1989, 257, F353-F358.
28. Mombouli, J.V.; Vanhoutte, J.M. Kinins and endothelial control of vascular smooth muscle. Ann. Rev. Pharmacol. Toxicol. 1995, 35, 679-705.
29. Bascands, J.L.; Pecher, C.; Bompart, G.; Rakotoarivony, J.; Tack, J.L.; Girolami, J.P. Bradykinin-induced in vitro contraction of rat mesangial cells via a B2 receptor type. Am. J. Physiol. 1994, 267, F871-F878.
30. Rodríguez-Barbero, A.; Martinez-Salgado, C.; López-Novoa, J.M.; Macías-Núñez, J.F. Perindopril stimulates cultured mesangial cells activation via bradykinin accumulation. Cell Physiol. Biochem. 1997, 7, 69-80.
31. Dixon, B.S.; Breckon, R.; Fortune, J.; Vavrek, R.J.; Stewart, J.M.; Marzec-Calvert, R.; Linas, S.L. Effects of kinins on cultured arterial smooth muscle. Am. J. Physiol. 1990, 258, C299-C308.
32. Dworkin, L.D.; Beinstein, J.A.; Parker, M.; Tolbert, E.; Feiner, D.H. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanism. Kidney Int. 1993, 43, 808-814.
33. Macías-Núñez, J.F.; García Iglesias, C.; Santos, J.C.; Sanz, E.; López-Novoa, J.M. Influence of plasma renin content, intrarenal AII, captopril and calcium channel blockers on the vasoconstriction and renin release promoted by adenosine in the kidney. J. Lab. Clin. Med. 1985, 106, 562-567.
34. Olivera, A.; Tomás, M.; López-Novoa, J.M. Effect of A1 and A2 agonists and antagonists on cAMP and Ca2+ in cultured rat mesangial cells. Am. J. Physiol. 1992, 262, C840-C845.
35. Montero, A., González-Sarmiento, R.; Rodríguez-Ló pez, A.M.; López-Novoa, J.M. Effect of verapamil on endothelin-1 induced proliferation in cultured rat mesangial cells. Cell Physiol. Biochem. 1995, 5, 155-66.
36. García-Cosmes, P.; Montero, A.; López-Novoa, J.M.; Macías-Núñez, J.F. Is renal protection with calcium antagonists possible? Drugs 1992, 44, 99-102.
37. Tschudi, M.R.; Noll, G.; Wenzel, R.R.; Lüscher, T.F. Calcium antagonists and endothelial function interaction with nitric oxide and endothelin. J. Cardiovasc. Pharmacol. 1997, 30 (suppl 3), S9-S17.
38. Dale, J.; Landrk, K.H.; Myhre, E. The effect of nifedipine, a calcium antagonist, on platelet function. Am. Heart J. 1983, 105, 103-105.
39. Pukerson, M.; Joist, J.H.; Greenberg, J.M; Kay, D.; Hoffstein, P.E.; Klahr, S. Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats. Tromb. Res. 1982, 26, 227-240.
40. Harris, J.P.D.C.H.; Chan, L.; Schrier, R.W. Remnant kidney hypermetabolism and progression of chronic renal failure. Am. J. Physiol. 1988, 254, F267-F276.